BR112012015433B8 - composição farmacêutica substancialmente anidra para aplicação cutânea - Google Patents

composição farmacêutica substancialmente anidra para aplicação cutânea Download PDF

Info

Publication number
BR112012015433B8
BR112012015433B8 BR112012015433A BR112012015433A BR112012015433B8 BR 112012015433 B8 BR112012015433 B8 BR 112012015433B8 BR 112012015433 A BR112012015433 A BR 112012015433A BR 112012015433 A BR112012015433 A BR 112012015433A BR 112012015433 B8 BR112012015433 B8 BR 112012015433B8
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
substantially anhydrous
anhydrous pharmaceutical
cutaneous application
cutaneous
Prior art date
Application number
BR112012015433A
Other languages
English (en)
Other versions
BR112012015433B1 (pt
BR112012015433A2 (pt
Inventor
Petersson Karsten
Original Assignee
Leo Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma As filed Critical Leo Pharma As
Publication of BR112012015433A2 publication Critical patent/BR112012015433A2/pt
Publication of BR112012015433B1 publication Critical patent/BR112012015433B1/pt
Publication of BR112012015433B8 publication Critical patent/BR112012015433B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

composição farmacêutica substancialmente anidra para aplicação cutânea é descrita uma composição farmacêutica compreendendo um derivado ou análogo de vitamina d como o ingrediente ativo dissolvido em uma mistura de solvente do agente tensoativo de três componentes é usada no tratamento de distúrbios ou condições dérmicas.
BR112012015433A 2009-12-22 2010-12-22 composição farmacêutica substancialmente anidra para aplicação cutânea BR112012015433B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DK2009000265 2009-12-22
DKPCT/DK009/000256 2009-12-22
US29310510P 2010-01-07 2010-01-07
US61/293105 2010-01-07
PCT/DK2010/000182 WO2011076207A2 (en) 2009-12-22 2010-12-22 Cutaneous composition comprising vitamin d analogue and a mixture of solvent and surfactants

Publications (3)

Publication Number Publication Date
BR112012015433A2 BR112012015433A2 (pt) 2016-03-15
BR112012015433B1 BR112012015433B1 (pt) 2019-04-24
BR112012015433B8 true BR112012015433B8 (pt) 2020-03-03

Family

ID=43618132

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012015433A BR112012015433B8 (pt) 2009-12-22 2010-12-22 composição farmacêutica substancialmente anidra para aplicação cutânea

Country Status (14)

Country Link
US (2) US20120322776A1 (pt)
EP (1) EP2515865B1 (pt)
JP (1) JP5873439B2 (pt)
CN (1) CN102781425B (pt)
AU (1) AU2010335654B2 (pt)
BR (1) BR112012015433B8 (pt)
CA (1) CA2785251A1 (pt)
HK (1) HK1177899A1 (pt)
IL (1) IL220514A (pt)
MX (1) MX2012007229A (pt)
NZ (1) NZ600999A (pt)
RU (1) RU2560677C2 (pt)
WO (1) WO2011076207A2 (pt)
ZA (1) ZA201204620B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5570442B2 (ja) * 2011-01-24 2014-08-13 株式会社シャネル化粧品技術開発研究所 水中油型乳化組成物及びその製造方法
JP6367819B2 (ja) * 2012-11-30 2018-08-01 レオ ファーマ アクティーゼルスカブ 活性化ｔ細胞におけるｉｌ−２２の発現の阻害方法
CN105899950B (zh) * 2013-12-19 2017-11-24 根特大学 鱼鳞中作为对于慢性应激的生物标记物的糖皮质激素的量化
CN104666312B (zh) * 2015-02-12 2017-11-07 重庆华邦制药有限公司 含有卡泊三醇和二丙酸倍他米松的制剂
CN106265485A (zh) * 2016-08-22 2017-01-04 江苏知原药业有限公司 一种稳定性改善的卡泊三醇组合物
CN106265511A (zh) * 2016-08-22 2017-01-04 江苏知原药业有限公司 一种性能优异的卡泊三醇倍他米松自微乳制剂
CN106442841B (zh) * 2016-12-16 2018-09-14 上海景峰制药有限公司 一种药物中阳离子表面活性剂的分离检测方法
US11433090B2 (en) 2017-06-16 2022-09-06 The Doshisha mTOR-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof
EP3741378A1 (de) 2019-05-23 2020-11-25 Dimitrios Tsakouridis Zusammensetzung zur topischen behandlung und pflege der psoriatischen haut

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639724A (en) * 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
JP2655190B2 (ja) * 1989-06-21 1997-09-17 エスエス製薬 株式会社 コルチコステロイド含有軟膏剤
ZA925581B (en) * 1991-07-26 1993-05-14 Smithkline Beecham Corp Pharmaceutical microemulsions.
US5766628A (en) * 1992-02-24 1998-06-16 Merz + Co. Gmbh & Co. Bath and shower composition having vesicle-forming properties and method for the production and use thereof
USRE39706E1 (en) 1993-01-15 2007-06-26 Leo Pharma A/S Crystalline form of a vitamin D analogue
DE69431310T2 (de) 1993-04-19 2003-05-22 Inst Advanced Skin Res Inc Mikroemulsionszubereitung enthaltend eine schwer absorbierbare substanz
GB9405304D0 (en) 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
GB9602111D0 (en) * 1996-02-02 1996-04-03 Unilever Plc Personal care composition
GB9611603D0 (en) * 1996-06-04 1996-08-07 Leo Pharm Prod Ltd Chemical compounds
FR2753377B1 (fr) * 1996-09-19 1999-09-24 Rhone Merieux Nouvelle association parasiticide a base de 1-n-phenylpyra- zoles et de lactones macrocycliques endectocides
US6432422B1 (en) * 1997-12-09 2002-08-13 Chugai Seiyaku Kabushiki Kaisha Creams containing vitamin D3 derivatives
US5989531A (en) * 1998-11-13 1999-11-23 Colgate-Palmolive Company Antiperspirant formulation for porous applicator
GB9903547D0 (en) * 1999-02-16 1999-04-07 Novartis Ag Organic compounds
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6582683B2 (en) * 2000-01-04 2003-06-24 Skinvisible Pharmaceuticals, Inc. Dermal barrier composition
WO2006120681A2 (en) * 2005-05-10 2006-11-16 Dermipsor Ltd. Compositions and methods for skin care
EP1331927B1 (en) * 2000-10-27 2007-12-12 Leo Pharma A/S Topical composition containing at least one vitamin d or one vitamin d analogue and at least one corticosteroid
US7005557B2 (en) * 2001-07-03 2006-02-28 The Procter & Gamble Company Film-forming compositions for protecting skin from body fluids and articles made therefrom
IL164163A0 (en) * 2002-04-09 2005-12-18 Pharmacia Corp Process for preparing a finely self-emulsifiable pharmaceutical composition
US20060189586A1 (en) * 2003-06-11 2006-08-24 Cleland Jeffrey L Pharmaceutical compositions comprising active vitamin D compounds
JP4608615B2 (ja) * 2003-06-17 2011-01-12 コグニス・アイピー・マネジメント・ゲーエムベーハー 皮膚引き締め用組成物中の変性大豆タンパク質
JP4939216B2 (ja) 2003-07-24 2012-05-23 レオ ファーマ アクティーゼルスカブ 新規アミノベンゾフェノン化合物
US8795693B2 (en) * 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US20090105336A1 (en) * 2004-04-19 2009-04-23 Strategic Science & Technologies, Llc Beneficial Effects of Increasing Local Blood Flow
WO2005123090A1 (en) * 2004-06-17 2005-12-29 Galderma S.A. Composition in spray form comprising a combination of a corticoid and a vitamin d derivative in an oily phase
FR2871694B1 (fr) * 2004-06-17 2008-07-04 Galderma Sa Composition pharmaceutique comprenant un onguent oleagineux et deux principes actifs solubilises
DK1828148T3 (da) 2004-12-13 2010-05-17 Leo Pharma As Triazolsubstituerede aminobenzophenonforbindelser
EP1827297A1 (en) * 2004-12-23 2007-09-05 Unilever Plc Water-in-oil emulsions for hair treatment
WO2006138056A1 (en) * 2005-06-15 2006-12-28 Apollo Pharmaceutical, Inc. Pharmaceutical composition comprising a mahonia aquifolium extract for the treatment of psoriasis
FR2887150B1 (fr) * 2005-06-17 2007-08-03 Galderma Res & Dev Composition pharmaceutique comprenant un elastomere organopolysiloxane et un principe actif solubilise
US20070249055A1 (en) * 2006-04-24 2007-10-25 The Procter & Gamble Company Method of measuring lotion and additive ingredient transfer
US20080260655A1 (en) * 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
FR2909284B1 (fr) * 2006-11-30 2012-09-21 Galderma Sa Nouvelles compositions sous forme d'onguent sans vaseline comprenant un derive de vitamine d et eventuellement un anti-inflammatoire steroidien
MX2009006593A (es) 2006-12-22 2009-07-02 Leo Pharma As Acetofenonas sustituidas utiles como inhibidores de fosfodiesterasa 4.
MX2009009238A (es) 2007-02-28 2009-09-08 Leo Pharma As Nuevos inhibidores de fosfodiesterasa.
EP1970049A1 (en) * 2007-03-15 2008-09-17 Drug Delivery Solutions Limited Polyaphron topical composition with vitamin D and corticosteroid
CN101677979A (zh) 2007-04-19 2010-03-24 利奥制药有限公司 Src家族激酶抑制剂
KR101959952B1 (ko) * 2007-04-25 2019-03-19 사이토크로마 인코포레이티드 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
WO2008141078A1 (en) 2007-05-11 2008-11-20 Sonneborn Inc. Petrolatums having silicone-like properties
US20080299156A1 (en) * 2007-06-01 2008-12-04 L'oreal Skin care compositions containing a high internal phase emulsion
MX2011006428A (es) 2008-12-19 2011-07-28 Leo Pharma As Triazolopiridinas como inhibidores de fosfodiesterasa para tratamiento de enfermedades dermicas.
JP2012531393A (ja) * 2009-06-29 2012-12-10 グラクソ グループ リミテッド 新規の医学的使用

Also Published As

Publication number Publication date
BR112012015433B1 (pt) 2019-04-24
JP5873439B2 (ja) 2016-03-01
RU2560677C2 (ru) 2015-08-20
AU2010335654A1 (en) 2012-07-26
CA2785251A1 (en) 2011-06-30
JP2013515018A (ja) 2013-05-02
CN102781425B (zh) 2014-08-13
NZ600999A (en) 2014-06-27
EP2515865B1 (en) 2016-12-14
WO2011076207A3 (en) 2012-03-01
CN102781425A (zh) 2012-11-14
BR112012015433A2 (pt) 2016-03-15
AU2010335654B2 (en) 2015-04-09
MX2012007229A (es) 2012-07-30
US20160324875A1 (en) 2016-11-10
RU2012130421A (ru) 2014-01-27
EP2515865A2 (en) 2012-10-31
IL220514A (en) 2017-01-31
WO2011076207A2 (en) 2011-06-30
HK1177899A1 (en) 2013-08-30
US20120322776A1 (en) 2012-12-20
ZA201204620B (en) 2013-09-25

Similar Documents

Publication Publication Date Title
BR112012015433B8 (pt) composição farmacêutica substancialmente anidra para aplicação cutânea
CO6680667A2 (es) Derivados ester de ácido borónico cíclico y sus usos terapéuticos
DOP2013000105A (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogénesis
MY167691A (en) A pharmaceutical spray composition comprising a vitamin d analogue and a corticosteroid
PE20151727A1 (es) Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-ciano-metil)-amidas sustituidas inhibidores de catepsina c
BR112012008823B8 (pt) compostos que modulam receptor de androgênio, composição farmacêutica compreendendo os ditos compostos e usos dos mesmos para a prevenção ou tratamento de distúrbios dependentes de receptores de androgênio
BR112015032623A2 (pt) composto, composição farmacêutica, métodos para tratar doenças e condições, e para degradar o receptor de estrogênio, usos de um composto e de uma combinação, e, combinação
BR112015000578A2 (pt) moduladores da via do complemento e usos dos mesmos
BR112012021086A2 (pt) composições farmacêuticas de composto espiro-oxindole para administração tópica e seu uso como agentes terapêuticos
UY33776A (es) Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso
BR112012006686B8 (pt) compostos de amida substituída, composições farmacêuticas contendo os ditos compostos, e uso dos mesmos para prevenir e/ou tratar doenças causadas pelo lpa
MX2011009847A (es) Agentes antihelminticos y su uso.
SMT201200017B (it) Nuovi antagonisti P2X7R e il loro uso.
ECSP14013200A (es) Una nueva composición terapéutica que contiene apomorfina como principio activo
ES2408343R1 (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
BR112014020113A8 (pt) Composições farmacêuticas e método para diminuir a frequência de micção
EP2361083A4 (en) COMPOSITION FOR THE TREATMENT OF EPITHELIAL TISSUE
AR077490A1 (es) Composiciones farmaceuticas topicas para el tratamiento de una condicion hiperproliferativa de la piel
MX2012007227A (es) Composicion farmaceutica que comprende analogo de vitamina d y mezcla de cosolvente-tensioactivo.
BR112012015437A2 (pt) composição tópica substancialmente anidra de armazenamento estável
CL2010001577A1 (es) Uso de nifurtimox para preparar un medicamento util en el tratamiento de enfermedades causadas por giardias.
IN2015DN01329A (pt)
CL2015001502A1 (es) Composición farmacéutica que comprende desloratadina y prendnisolona y uso de la misma.
BR112013000296A2 (pt) agentes terapêuticos 976
BR112018070064A2 (pt) composições farmacêuticas estáveis para administração tópica e uso das mesmas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/12/2010, OBSERVADAS AS CONDICOES LEGAIS. (CO) 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/12/2010, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant

Free format text: REF. RPI 2520 DE 25/04/2019 QUANTO A PRIORIDADE UNIONISTA.